T Cell Receptors, Tumor Infiltrating Lymphocytes
Modified T Cell Receptors (TCR) are being investigated as a promising option for the treatment of solid tumors and virus infections. Efforts are underway to optimize the TCR alpha and beta transgene pairing to enhance the functional activity of the cell. Autologous therapies using Tumor Infiltrating Lymphocytes (TIL) are also being developed to treat solid tumors. There are an estimated 60 treatments in development ranging from preclinical to phase II stage that are utilizing TCR or TIL as a potential approach to target lymphoma, leukemia, and various solid tumors. The Catalent Cell Therapy team has expertise through various programs underway in both TCR and TIL manufacturing from bench to commercial readiness phase.